Method of producing pilles

专利摘要:
A pharmaceutical composition with a retarded liberation of an active material and a process for producing the same are disclosed. An active material in finely divided form is mixed with both a finely divided high melting lipid or lipoid component and a finely divided low melting lipid or lipoid component, the resulting mixture is brought to a temperature which is above the melting point of the low melting component but below the melting point of the high melting component and the mixture, after melting of the low melting component, is allowed to cool to below the melting point thereof and subsequently worked up to give a finished pharmaceutical composition which has a controlled retarded liberation and which is safe, easy and not expensive to produce.
公开号:SU1360575A3
申请号:SU813304330
申请日:1981-06-26
公开日:1987-12-15
发明作者:Аугарт Хельмут
申请人:Гедеке А.Г. (Фирма)；
IPC主号:

专利说明:

You will relate to the chemical and pharmaceutical industry and to the preparation of tablets.
The chain of the invention is to extend the release time of the active substance.
The chain is achieved by using a mixture of low and 1 DOV LIS-1DOV mixtures in the short circuit. with a high temperate urauyusha at a correspondence of 1s9–9 oscheaii: they are appropriately heated to a temperature that increases the melting point of the pellet with a hawk of melting temperature C but the melting point of the component with a high T8f.fflepa-rypoii of 70 ° C and 100 ° С then they are allowed to cool to temperatures below us. TOCH1Sh melting s
The method is implemented as follows: 6PSSOM,;
Initially, a-yo powder is prepared, a mixture of active material or materials, lipid J1I lipoid kompozentoBe napolnitsp and disintegrating materials or swelling agents (controlling cosyunents are released in a free state)
After perezmeg nzavi to get od1. Its native mixture is NRG; p. Rekegsh-za-iggi heats E1YuT as long as the component G with a 1-hp temperature zone is not on the che; it sews tgcrc and mass
Wasp Abpeni of the Emperor with Shtisky Hamparptu Swarm of Schwarzsch Airborne Replacement. {nozshshno; with the application of the non-canal / hour pressure after cooling. It turns out the spec-ga and with nassa prak7 g gesset without pores with
H full gogshchpat materkap-n can rnyvn; -rTb lactose, sa; shroya and phosphate caldil V Ls; s1 ngrnr-u a1a; kmy agent ™ w / Kln ogsukhepelyshi atentagsh ,. which are cnysaT for the connoisseurs of the discharge in the freeE- T state of the acti va 5a x maternyllob ,, for example; soluble to VOD2 .nli pabugsayggae in Eoda s-Ja- tar at. such ;; as methylcelpazo, - razptz. ZH (e Sinta geshshee polymers j natural materials; 5 for example, the body and the level of the resin, nredpgg gito car br; kaimtilstiltselyutosa S
The mixing is made in a b strong aiiptne with a low speed of over-Sh; shvaHv .iK or v ;;; speed-kneading machine with С-absorber ng-g screw I ;; „
 Rasgshava po.puchasht in pseadooo} to: the genic layer of torus granules
five
0
0
five
five :
0
0
fluidized bed drying apparatus, as in such apparatus can be easily reached the necessary temperature. Friction mixing apparatuses are also suitable, since in this case it is not necessary to conduct heating, because the powder mixtures are sufficiently heated in a few minutes at 1000–1500 rpm. Finally, you can also use toothed wheel granulating machines; as they allow operation with very high throughput. Powder mixtures can be extruded without pores at a low pressure and at temperatures of about 50 ° C.
After melting and before cooling, it is preferable to compress the Ness 1 by additionally using appropriate mechanical devices, for example, extruders for friction mixers,
After compression, the mass can be granulated with Pb by any of the appropriate methods during cooling or after it. Lubricants can be added to the granules. The granules can be pressed to form tablets, which can be prepared in the free state of the active material by appropriate formulation of the composition. You can also get a tease or cover them with a shell. The distal granules can also be created in the form of multi-layered tablets, for example, in the form of bilayer tablets, the second layer of which contain: an immediate initial dose. The granules can also be coated firmly with gelatinous hybrids. ,
1 o The known method (melting at -100 C) o
The powder mixture is heated in a mixing apparatus with a low stirring speed at 100 ° C, stirred for 15 i-tn and the mass after the addition to the temperature of the surrounding medium is granulated. From this, tablets with a specific specificity are pressed (tablet diameter 11 i / ai thickness 5.2 gprochnost on a gap of 90 N) o
II The proposed method (melting at)
A) The powder mixture is heated to a high speed mixer. The mixture is kept for 5 minutes and granulated after cooling to ambient temperature. From this mass, tablets are pressed, the specifications of which are described above,
B) The powder mixture is introduced into a granulator with gear wheels, the rollers of which were heated to approximately warm water. The mass is extruded through the holes under the rollers at 54 s. The granules obtained through this sieve are granulated in order to compress tabs from them. Years with the specified specification
B) The powder mixture is heated to a low-speed planetary mixer, stirred for 15 minutes and the mass is granulated after cooling to ambient temperature, then pressed into tablets with the specified specification.
D) The powder mixture is heated in the fluidized bed of the granulator, occasionally agitated, with air supply at, and the temperature of the product. After cooling, the mass is pressed to obtain tablets having the specified specification.
E) The powder mixture is rotated at a speed of 1300 rpm in a friction mixer until it melts. Melting component
g
five
0
-
0
five
with a low melting point occurs at 4 minutes. The mass is removed from the blender and, after cooling to ambient temperature, it is granulated, then tablets with the specified specification are pressed.
ill. Method of pressing without melting
A) The powder mixture is heated in a high-speed mixer to 50 e, i.e. below the melting point of the low melting point component, it is cured for 5 minutes and after cooling to ambient temperature, it is granulated, then tablets with the specified specification are pressed.
B) The powder mixture is pressed without heating at ordinary pressure in order to obtain tablets with the specified specification, tensile strength of the tablets is 72 N.
B) The powder mixture was pressed without heating at the highest possible pressure in order to obtain tablets with a tensile strength of 88 N. Because of the high pressure, the thickness of the tablets was 4.8 mm.
The table shows what percentage of the composition was .disintegrated1 after the given time of de-integration.
1360575
The table below shows that
The compositions obtained according to method 1 are fully consistent with the disintegration time, the products obtained by method II. However, the products obtained by method III using simple npeccoBaiffH, even at the highest possible pressure, do not give beneficial retardation. After 2 hours, the formulations disintegrated almost completely. Example 1 o Coated tablets containing 45 mg of norfenephrine.
The composition of the raw material, g:
Lactose2700
Norfenefrin Hydrochloride 1000
Carboxymethylcellulose50
Hydrogenated
castor
oil 250
Stearinova
acid1000
Dp production slowing tablets all of these components are placed in a high-speed mixer with two walls and mixed until a homogeneous mass. Double
stengs are heated until the mixture reaches temperature. The mass is cured and removed with cooling to ambient temperature. The cooled mass is granulated, then pressed tablets with a diameter of 9 mm and a weight of 225 mg, after which the tablets are coated with a thin shell
Example 2 „Tablets containing 15 mg of norfenephrine hydrochloride Ingredients J, g g Lactose 2700
Norfenefrina1000 Hydrochloride
Carboxymethyl cellulose50
1583 P-castor oil Stearinova
acid: from 1000
Granules obtained from the components according to the method described in example 1,
then pills weighing 95 ng are pressed
and about mmo diameter
Example Zo Tablets containing 80 mg of pentazritritilya tetranitrate
0
0
five
five
0
s
5Q
.-.-
3200 500
50 2500 1000
40
45
The composition of the raw material, g:
Tetranitrate
pentaerythritol
(16%)
Lactose
Carboxymethyl
cellulose
Hydrogenated
Castor oil
Stearinova
acid.
For the production of the retarding tablets, the powdered raw materials are introduced into a two-wall planetary mixer, stirred until a homogeneous mixture is obtained, and heated until the temperature of the powder mixture is reached, then cured. The mass, still warm, is removed from the agitator and, after cooling, granulated, then tablets are prepared all the time. catfish 750 mg and a diameter of 11 mm,
PRI me R 4. Tablets containing 45 mg of HC1 norfenefrinao
The composition of the raw material, g:
Lactose
HC1 Norfenefrina
Carboxymethylcellulose
Magnesium stearate
Stearinova
acid.
For production
tablet release; all substances are stirred until a homogeneous mixture is obtained in a planetary mixer f. double lined. The double plate is heated until the temperature of the mixture reaches. After solidification, the mass is removed, cooled and granulated. Granules are pressed into tablets with a diameter of 9 mm
and weighing 225 mg, i
Example 5, Tablets containing 45 mg of isosorbide dinitrate.
The composition of the raw material, g:
Isosorbide dinitrate,
ground in to lactose
(25%) 240
Lactose145
Carboxymethylcellulose5
Hydrogenated
castor
butter25
Stearinova
acid100
2430 900
45 450
675 supporters
71360575
The powders are mixed until a homogeneous mixture is obtained, the mixture is heated to a double-lined boiler. The warm mass is passed through a 5-hole wide screen. After cooling, the mass is granulated and pressed into oval tablets weighing 343.3 mg.
with
Example 6o Tablets containing 30 mg of vincamine.
The composition of the raw material, g:
HC1 vinkomina73,33
Lactose 296.67
Carboxymethylcellulose5
Hydrogenated
castor
butter25
Stearinova
acid100
All components are thoroughly mixed and heated to 60 ° C in a water bath. Warm mass is passed through graiul bargaining
After cooling, the mass is granulated, and then pressed into tablets with a diameter of 9 mm and a weight of 225 mg
Example 7, Tablets with a slow release of a biologically active film-coated substance containing 90 mg diltsemine
The composition of the raw material, kg:
Diltiazem
hydrochloride6,000
Lactose16,300
Stearinova
acid DAS4,500
Hydrogenated
castor
oil3,000
Carboxymethyl
Na cellulose
0-, 300
The powder is stirred and heated in a mixer with warm water up to 60 ° C. After cooling, the resulting mass is granulated on a 2 mm sieve. From the granules, convex tablets with a diameter of 11 mm, a thickness of 5 mm, and a weight of 451.5 mm are pressed.
8.5 mg of hydroxypropylmethylcellulose in 10% aqueous solution is applied to the tablets and dried with warm air at a temperature of 40 C.
Example 8, tablets with slow. by the release of a biologically active substance, the content of 60 mg is diltiazem.
The composition of the raw material, kg:
eight
 five
15
0
five
thirty
Diltiazem
hydrochloride 4.8
Lactose13,04
with hydrated
castor
oil2,4
Stearinova
DAS3,6 acid
0 Carboxymethylcellulose Na0,240
The powder is mixed and heated in a mixer with heating with warm water to. The resulting mass is then ground into granules on a 2 mm sieve. From this granulate, tablets with a diameter of 10 mn, a thickness of 3.3 mm, and a weight of 301 mW are pressed.
Note 8r9. Isosorbidinitrate (tablets)
The composition of the raw material, g:
Stearinova
acid384
Hydrogenated
castor
oil200
Lactose1216
Isosorbid D-Nitrate 400
Carboxymethyl cellulose Na24
Magnesium stearate 8
Stearic acid, hydrogenated castor oil is mixed with isosorbiddinitrate. The mixture is heated before and granulated through a sieve with a mesh size of 1 mm. The remaining powders are added to the granulate in a swing mixer. From this mass, tablets are pressed with a diameter of 6 mm and a weight of 111.6 mg, which corresponds to 20 mg of isosorbidinitrate per tablet
0
 Tablets can be taken directly as a medication dose of 20 mg as tablets with delayed decomposition, 2-4 tablets can be placed in a hard gelatin capsule.
Example 10 Tablets with a slow release of a biologically active substance containing 5 mg of carbuterol.
Composition sf, g:
Carbuterol-HC1568
Lactose 6000
Pigment yellow
E 172 (iron oxide yellow) 52
9
D; wake up -si-rraHa 50 Hydrated castor
butter1200
Stearic acid5 powder DAS1200
Carboxyl
cell Na80
Powders grind and mix. The powder mixture is heated to 60 and 10 ivfflH is kneaded in a mixer. The mass is granulated through a 1-millimeter OA adtoe After cooling, a tablet is pressed weighing 91.503 mg in diameter with a diameter of 6 mm and a thickness of 3j6 mm
Tablets contain 5568 g of Tob carbuterol hydrochloride, 5 mg. Carboterol.,
1360575
Phenobarbital 0.875 PETN 16.6% 9.0
Lactose 0.75
5Stearinova
DAS2.75 acid
Hydrogenated
castor
oil0,688
Kar b o si methylcellulose Na0,137
Iron oxide
pigment yellow
E1720,006
Instantly receive layer
ten
of
Phenobarbital 0.25
PETN 16.6% -3.0
Lactose 1.85
Polyethylene glycol 40000,625 Iron oxide pigment yellow E172 0.001 The starting products are mixed, then heated with steam to 70 ° C and the mass is cooled after grinding.
Example 11 of PE III - phenobarbital - bilayer tablets with the largest amount of biologically active substance
The protracted active layer is obtained from the composition of a kg:
of
Phenobarbital 0.25
PETN 16.6% -3.0
Lactose 1.85
Polyethylene glycol 40000,625 Iron oxide pigment yellow E172 0.001 The starting products are mixed, then heated with steam to 70 ° C and the mass is cooled after grinding.

权利要求:
Claims (1)
[1]
METHOD FOR PRODUCING TABLETS by mixing the lipid component with the active substance by heating followed by compression, characterized in that, in order to extend the release time of the active substance, a mixture of lipids with a low and high melting point at a ratio of : 9-9: 1 is used as a lipid component respectively, and heated to a temperature exceeding the melting point of the component with a low melting point of 40-70 ° C, but below the melting point of the component with a high melting point of 70-100 ° C, and then cooling ute to a temperature below its melting point.
§ ω s
1360575 AZ

类似技术:

---

公开号 | 公开日 | 专利标题

---

SU1360575A3|1987-12-15|Method of producing pilles

---

RU2069558C1|1996-11-27|Method of cholestyramine tablet producing

---

CN107875136B|2021-03-05|Amoxicillin medicinal preparation and preparation method thereof

---

US4150110A|1979-04-17|Coated granules of polyacrylic alkali metal salts and method of producing same

---

WO2003061646A1|2003-07-31|Process for producing granules containing branched amino acids

---

EP0728519B1|2002-04-17|High speed agitated granulation method and high speed agitated granulating machine

---

FI68762B|1985-07-31|PRESSURE FOUNDATION FOR FRAME SUPPLY

---

CN108567759B|2019-06-04|A kind of valsartan and Hydrochlorothiade piece and preparation method thereof

---

CN108926524B|2020-07-17|Instant gelatin product block and preparation method thereof

---

BRPI0609342A2|2010-03-30|agglomerated starch compositions

---

US2005730A|1935-06-25|Casein products and process of making

---

CN107867964B|2021-03-12|Gas production agent and preparation method thereof

---

CN110623936A|2019-12-31|Preparation method of composition containing medicine meloxicam and auxiliary material

---

US5152822A|1992-10-06|Slow release oxamide fertilizer

---

CZ286197B6|2000-02-16|Process for preparing tablets of fusidic acid sodium salt and granulate for such preparation process

---

JPH05105636A|1993-04-27|Antacid agent composition

---

CN110051639B|2021-08-31|Rapidly disintegrating nicergoline tablet and preparation method thereof

---

CN110623961A|2019-12-31|Composition containing medicine meloxicam and auxiliary material

---

RU2191573C1|2002-10-27|Method of doxycycline-base antibacterial agent preparing

---

WO2000072828B1|2001-02-08|A method of tabletting dose units of active agents

---

CN1149079C|2004-05-12|Process for preparing micro pills containing medicine by high-speed stirring and fusion

---

RU2238100C2|2004-10-20|Biologically active supplement "mumivit"

---

RU2171673C1|2001-08-10|Pharmaceutical composition and method of its preparing

---

RU2135163C1|1999-08-27|Method of "ortophen" tabletted form producing

---

RU2003125160A|2005-02-10|A PRODUCT CONTAINING WATER-SOLUBLE SALTS OF TRITERPENIC ACIDS AND METHOD FOR PRODUCING IT

同族专利:

---

公开号 | 公开日

---

DD159966A5|1983-04-20|

---

DK155711C|1989-10-23|

---

IE811438L|1981-12-28|

---

ZA814094B|1982-07-28|

---

FI811951L|1981-12-29|

---

ES503414A0|1983-01-01|

---

DK278381A|1981-12-29|

---

ES8301625A1|1983-01-01|

---

FI76928B|1988-09-30|

---

US4483847A|1984-11-20|

---

DE3024416A1|1982-01-21|

---

EP0043254B1|1984-05-30|

---

EP0043254A1|1982-01-06|

---

DK155711B|1989-05-08|

---

CA1165691A|1984-04-17|

---

FI76928C|1989-01-10|

---

AU545279B2|1985-07-11|

---

JPS5738711A|1982-03-03|

---

IE51353B1|1986-12-10|

---

DE3163868D1|1984-07-05|

---

DE3024416C2|1982-04-15|

---

JPS6140204B2|1986-09-08|

---

AU7206981A|1982-01-07|

---

HU184862B|1984-10-29|

---

AT7655T|1984-06-15|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

---

US2875130A|1956-11-20|1959-02-24|Smith Kline French Lab|Method of preparing sustained release particles and the product of the method|

---

GB906422A|1958-05-02|1962-09-19|Wellcome Found|Improvements in and relating to prolonged acting pharmaceutical preparations|

---

US3108046A|1960-11-25|1963-10-22|Smith Kline French Lab|Method of preparing high dosage sustained release tablet and product of this method|

---

US3146167A|1961-10-05|1964-08-25|Smith Kline French Lab|Method of preparing sustained release pellets and products thereof|

---

GB1021924A|1962-06-22|1966-03-09|Smith Kline French Lab|Improvements in or relating to method of preparing sustained release tablets|

---

US3279998A|1962-06-22|1966-10-18|Smith Kline French Lab|Method of preparing sustained release tablets|

---

US3308217A|1965-02-09|1967-03-07|Lowy Lawrence|Method of granulating materials for subsequent forming into tablets|

---

US4132753A|1965-02-12|1979-01-02|American Cyanamid Company|Process for preparing oral sustained release granules|

---

US3374146A|1966-04-18|1968-03-19|American Cyanamid Co|Sustained release encapsulation|

---

US3487138A|1966-11-23|1969-12-30|Merck & Co Inc|Process for preparing a delayed release medicinal tablet|

---

DE1617418C3|1967-12-16|1980-01-24|Hoechst Ag, 6000 Frankfurt|Manufacture of solid drug forms with delayed release of active ingredients|

---

SE335202B|1968-06-19|1971-05-17|Aco Laekemedel Ab|

---

GB1312918A|1969-07-08|1973-04-11|Beecham Group Ltd|Veterinary treatment|

---

DK121813B|1969-12-10|1971-12-06|C Mangen|Process for the preparation of tablet-like dosage units.|

---

DE2426811A1|1974-06-04|1976-01-08|Klinge Co Chem Pharm Fab|PROCESS FOR THE MANUFACTURING OF RETARD TABLETS|JPS5959632A|1982-09-28|1984-04-05|Teikoku Chem Ind Corp Ltd|Sustained release composition|

---

US4713245A|1984-06-04|1987-12-15|Mitsui Toatsu Chemicals, Incorporated|Granule containing physiologically-active substance, method for preparing same and use thereof|

---

JPH0545568B2|1984-08-16|1993-07-09|Shionogi Seiyaku Kk|

---

US4755387A|1985-03-21|1988-07-05|The Procter & Gamble Company|Therapeutic particles|

---

FR2581541B1|1985-05-09|1988-05-20|Rhone Poulenc Sante|NOVEL PHARMACEUTICAL COMPOSITIONS FOR THE EXTENDED RELEASE OF AN ACTIVE INGREDIENT AND THEIR PREPARATION METHOD|

---

US4820523A|1986-04-15|1989-04-11|Warner-Lambert Company|Pharmaceutical composition|

---

US4837381A|1986-08-11|1989-06-06|American Cyanamid Company|Compositions for parenteral administration and their use|

---

US4822619A|1987-02-18|1989-04-18|Ionor, Inc.|Controlled release pharmaceutical preparation containing a gastrointestinal irritant drug|

---

JP2668880B2|1987-06-23|1997-10-27|日本油脂株式会社|Method for producing coated amino acids|

---

DE3737741A1|1987-11-06|1989-05-18|Goedecke Ag|ORAL MEDICAL FORM FOR THE ONLY DAILY TREATMENT OF HYPERTENSION WITH DILTIAZEMHYDROCHLORIDE|

---

JP2681373B2|1988-07-18|1997-11-26|塩野義製薬株式会社|Method for manufacturing sustained-release preparation|

---

EP0418596A3|1989-09-21|1991-10-23|American Cyanamid Company|Controlled release pharmaceutical compositions from spherical granules in tabletted oral dosage unit form|

---

US5213810A|1990-03-30|1993-05-25|American Cyanamid Company|Stable compositions for parenteral administration and method of making same|

---

IE61651B1|1990-07-04|1994-11-16|Zambon Spa|Programmed release oral solid pharmaceutical dosage form|

---

US5134016A|1990-10-31|1992-07-28|E. I. Du Pont De Nemours And Company|Fiber reinforced porous sheets|

---

US5266331A|1991-11-27|1993-11-30|Euroceltique, S.A.|Controlled release oxycodone compositions|

---

US5968551A|1991-12-24|1999-10-19|Purdue Pharma L.P.|Orally administrable opioid formulations having extended duration of effect|

---

US5958459A|1991-12-24|1999-09-28|Purdue Pharma L.P.|Opioid formulations having extended controlled released|

---

US7740881B1|1993-07-01|2010-06-22|Purdue Pharma Lp|Method of treating humans with opioid formulations having extended controlled release|

---

DE59302200D1|1992-05-22|1996-05-15|Goedecke Ag|METHOD FOR PRODUCING RETARDED DRUG PREPARATIONS|

---

NZ260408A|1993-05-10|1996-05-28|Euro Celtique Sa|Controlled release preparation comprising tramadol|

---

US5891471A|1993-11-23|1999-04-06|Euro-Celtique, S.A.|Pharmaceutical multiparticulates|

---

KR100354702B1|1993-11-23|2002-12-28|유로-셀티크 소시에떼 아노뉨|Manufacturing method and sustained release composition of pharmaceutical composition|

---

IL110014A|1993-07-01|1999-11-30|Euro Celtique Sa|Solid controlled-release oral dosage forms of opioid analgesics|

---

US5879705A|1993-07-27|1999-03-09|Euro-Celtique S.A.|Sustained release compositions of morphine and a method of preparing pharmaceutical compositions|

---

US5843480A|1994-03-14|1998-12-01|Euro-Celtique, S.A.|Controlled release diamorphine formulation|

---

US5478577A|1993-11-23|1995-12-26|Euroceltique, S.A.|Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level|

---

GB9422154D0|1994-11-03|1994-12-21|Euro Celtique Sa|Pharmaceutical compositions and method of producing the same|

---

US5965161A|1994-11-04|1999-10-12|Euro-Celtique, S.A.|Extruded multi-particulates|

---

EP0818990A1|1995-04-03|1998-01-21|Abbott Laboratories|Homogeneous mixtures of low temperature-melting drugs and additives for controlled release|

---

DE19522899C1|1995-06-23|1996-12-19|Hexal Pharmaforschung Gmbh|Process for the continuous sintering of a granulate|

---

AT386506T|1995-10-17|2008-03-15|Jagotec Ag|ADMINISTRATION OF UNSUCCESSFUL MEDICINAL PRODUCTS|

---

US6465016B2|1996-08-22|2002-10-15|Research Triangle Pharmaceuticals|Cyclosporiine particles|

---

US7255877B2|1996-08-22|2007-08-14|Jagotec Ag|Fenofibrate microparticles|

---

DE19705538C1|1997-02-14|1998-08-27|Goedecke Ag|Process for the separation of active substances in solid pharmaceutical preparations|

---

US5891476A|1997-12-22|1999-04-06|Reo; Joe P.|Tastemasked pharmaceutical system|

---

WO1999040906A2|1998-02-11|1999-08-19|Research Triangle Pharmaceuticals|Method and composition for treatment of inflammatory conditions|

---

US6979456B1|1998-04-01|2005-12-27|Jagotec Ag|Anticancer compositions|

---

WO1999061001A1|1998-05-29|1999-12-02|Rtp Pharma Inc.|Thermoprotected microparticle compositions and process for terminal steam sterilization thereof|

---

AT252889T|1998-08-19|2003-11-15|Skyepharma Canada Inc|INJECTABLE AQUEOUS PROPOFOL DISPERSIONS|

---

US6806294B2|1998-10-15|2004-10-19|Euro-Celtique S.A.|Opioid analgesic|

---

IL143197D0|1998-11-20|2002-04-21|Rtp Pharma Inc|Dispersible phospholipid stabilized microparticles|

---

DE19918325A1|1999-04-22|2000-10-26|Euro Celtique Sa|Extruded drug dosage form, e.g. granulate for tableting, comprising an active agent in a polysaccharide-containing matrix, giving a release profile which is controllable by extrusion conditions and/or the inclusion of additives|

---

US8663692B1|1999-05-07|2014-03-04|Pharmasol Gmbh|Lipid particles on the basis of mixtures of liquid and solid lipids and method for producing same|

---

US10179130B2|1999-10-29|2019-01-15|Purdue Pharma L.P.|Controlled release hydrocodone formulations|

---

ES2374717T3|1999-10-29|2012-02-21|Euro-Celtique S.A.|FORMULATIONS OF CONTROLLED RELEASE HYDROCODONE.|

---

CN1313080C|2000-04-20|2007-05-02|斯凯伊药品加拿大公司|Improved water-insoluble drug particle process|

---

ES2325057T3|2000-08-31|2009-08-25|Jagotec Ag|MOLDED PARTICLES.|

---

US8586094B2|2000-09-20|2013-11-19|Jagotec Ag|Coated tablets|

---

KR101045144B1|2000-10-30|2011-06-30|유로-셀티크 소시에떼 아노뉨|Controlled release hydrocodone formulations|

---

AT373471T|2000-12-27|2007-10-15|Ares Trading Sa|LIPID MICROPARTICLES BY CRYOGENIC MICRONIZATION|

---

US7776314B2|2002-06-17|2010-08-17|Grunenthal Gmbh|Abuse-proofed dosage system|

---

US10668060B2|2009-12-10|2020-06-02|Collegium Pharmaceutical, Inc.|Tamper-resistant pharmaceutical compositions of opioids and other drugs|

---

DE10300325A1|2003-01-09|2004-07-22|Hexal Ag|Granules with oily substance, manufacturing process and tablet|

---

EP1594468A2|2003-02-03|2005-11-16|Novartis AG|Process for preparing a solid dispersion pharmaceutical product|

---

US20070048228A1|2003-08-06|2007-03-01|Elisabeth Arkenau-Maric|Abuse-proofed dosage form|

---

US8075872B2|2003-08-06|2011-12-13|Gruenenthal Gmbh|Abuse-proofed dosage form|

---

DE10336400A1|2003-08-06|2005-03-24|Grünenthal GmbH|Anti-abuse dosage form|

---

WO2005123039A1|2004-06-12|2005-12-29|Collegium Pharmaceutical, Inc.|Abuse-deterrent drug formulations|

---

DE102004032051A1|2004-07-01|2006-01-19|Grünenthal GmbH|Process for the preparation of a secured against misuse, solid dosage form|

---

DE102005005446A1|2005-02-04|2006-08-10|Grünenthal GmbH|Break-resistant dosage forms with sustained release|

---

DE102005005449A1|2005-02-04|2006-08-10|Grünenthal GmbH|Process for producing an anti-abuse dosage form|

---

US20080075770A1|2006-07-21|2008-03-27|Vaughn Jason M|Hydrophilic abuse deterrent delivery system|

---

DE102007011485A1|2007-03-07|2008-09-11|Grünenthal GmbH|Dosage form with more difficult abuse|

---

US20110059140A1|2007-12-21|2011-03-10|Gerhard Winter|Extruded rod-shaped devices for controlled release of biological substances to humans and animals|

---

US8383152B2|2008-01-25|2013-02-26|Gruenenthal Gmbh|Pharmaceutical dosage form|

---

MX2010012039A|2008-05-09|2010-11-30|Gruenenthal Gmbh|Process for the preparation of an intermediate powder formulation and a final solid dosage form under usage of a spray congealing step.|

---

ES2560210T3|2009-07-22|2016-02-17|Grünenthal GmbH|Tamper-resistant dosage form for oxidation-sensitive opiates|

---

NZ596667A|2009-07-22|2013-09-27|Gruenenthal Chemie|Hot-melt extruded controlled release dosage form|

---

US9579285B2|2010-02-03|2017-02-28|Gruenenthal Gmbh|Preparation of a powdery pharmaceutical composition by means of an extruder|

---

ES2487244T3|2010-09-02|2014-08-20|Grünenthal GmbH|Handling resistant dosage form comprising an anionic polymer|

---

RU2604676C2|2010-09-02|2016-12-10|Грюненталь Гмбх|Destruction-resistant dosage form containing an inorganic salt|

---

NO2736495T3|2011-07-29|2018-01-20|

---

SI2736497T1|2011-07-29|2017-12-29|Gruenenthal Gmbh|Tamper-resistant tablet providing immediate drug release|

---

WO2013127831A1|2012-02-28|2013-09-06|Grünenthal GmbH|Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer|

---

AR090695A1|2012-04-18|2014-12-03|Grünenthal GmbH|PHARMACEUTICAL DOSAGE FORM RESISTANT TO ADULTERATION AND RESISTANT TO IMMEDIATE RELEASE OF DOSE|

---

US10064945B2|2012-05-11|2018-09-04|Gruenenthal Gmbh|Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc|

---

US9737490B2|2013-05-29|2017-08-22|Grünenthal GmbH|Tamper resistant dosage form with bimodal release profile|

---

CA2907950A1|2013-05-29|2014-12-04|Grunenthal Gmbh|Tamper-resistant dosage form containing one or more particles|

---

MX368846B|2013-07-12|2019-10-18|Gruenenthal Gmbh|Tamper-resistant dosage form containing ethylene-vinyl acetate polymer.|

---

CN105934241B|2013-11-26|2020-06-05|格吕伦塔尔有限公司|Preparation of powdered pharmaceutical composition by cryogenic grinding|

---

EP3142646A1|2014-05-12|2017-03-22|Grünenthal GmbH|Tamper resistant immediate release capsule formulation comprising tapentadol|

---

US9872835B2|2014-05-26|2018-01-23|Grünenthal GmbH|Multiparticles safeguarded against ethanolic dose-dumping|

---

US20160310429A1|2015-04-24|2016-10-27|Grünenthal GmbH|Tamper-resistant dosage form with immediate release and resistance against solvent extraction|

---

US10842750B2|2015-09-10|2020-11-24|Grünenthal GmbH|Protecting oral overdose with abuse deterrent immediate release formulations|

---

WO2017222575A1|2016-06-23|2017-12-28|Collegium Pharmaceutical, Inc.|Process of making more stable abuse-deterrent oral formulations|

---

EP3492070A1|2017-11-30|2019-06-05|BIT Pharma GmbH|Process and device for preparing a solid dispersion|

法律状态:

优先权:

---

申请号 | 申请日 | 专利标题

---

DE3024416A|DE3024416C2|1980-06-28|1980-06-28|Process for the production of medicaments with sustained release of active substances|

---